Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer.

Malmo, Sweden, September 26, 2018 - Hoylu, a leading enterprise collaboration releases from GlobeNewswire by registering your e-mail address below. 27 januari 2021 Immunicum AB (publ) planerar att expandera

GlobeNewswire - 18 feb 21 kl. 08:00 Immunicum AB (publ) publicerar bokslutskommuniké 2020. Pressmeddelande 18 februari 2021 Immunicum AB (publ) publicerar bokslutskommuniké 2020 OKTOBER - DECEMER I SAMMANDRAG Nettoomsättning för kvartalet uppgick till - (-)*.Periodens resultat uppgick till KSEK -47 568 (-19 409)*.Resultat per aktie före och efter utspädning uppgick till SEK -0,57 (-0,26)*. Immunicum AB (publ; IMMU.ST) provided today an update on planned, ongoing and previously completed clinical trials for its lead program, ilixadencel. Ilixadencel is a cell-based treatment with therapeutic potential as a component of combination regimens for a range of solid tumor cancers. 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.

Immunicum ab email format

Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) Eva Mulder and Sophia Hergenhan, Ph.D. Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Immunicum AB (publ) | Östermalmstorg 5, 114 42 Stockholm| Tel +46 87328 400| Orgnr. 556629-1786|immunicum.se .

Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival E-mail: ir@immunicum.com. The Company's Certified Adviser is Redeye AB Telephone: +46 (0) 8 545 013 31 www.redeye.se.

2021-04-12 · Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com.

556629-1786|immunicum.se . MEDIA RELATIONS Gretchen Schweitzer and Joanne Tudorica . Trophic Communications .

Aktiehistorik, Immunicum AB På skatteverket.se använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.

31 December 2020. Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepato Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020. Investors, media and the public are welcome to join. Immunicum AB (publ) Announces Upcoming Oral Presentation on MERECA Trial at the ASCO-SITC Clinical Immuno-Oncology Symposium 20 December 2019 Read more Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO 13 December 2019 Read more R Immunicum AB (publ) Interim Report January – September 2019 6 November 2019 Read more R Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com. Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations . Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) IMMUNICUM: FÅR FAST TRACK FRÅN FDA FÖR ILIXANDENCEL MOT GIST. STOCKHOLM (Nyhetsbyrån Direkt) Immunicum har erhållit snabbspårsstatus, så kallad Fast Track Designation, från den amerikanska läkemedelsmyndigheten, FDA, för bolaget Immunicum.

2020-09-21 Senaste nyheter om - Immunicum, aktieanalys, kursutveckling och rapporter. Immunicum komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. email this chart printer-friendly format. 03:05 AM ET Headlines for Immunicum AB (OME:IMMU) News for Immunicum AB. More. Company Releases for Immunicum AB. Friday, April 02, 2021. Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020.
Sommarjobb äldreboende jönköping

Joanne Tudorica and Sophia Hergenhan, Ph.D. Trophic Communications Telephone: +49 171 351 2733 E-mail: ir@immunicum.com. About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Com Immunicum. Immunicum AB (publ) meddelar att patientrekryteringen till Fas Ib-delen av kombinationsstudien ILIAD är slutförd.

Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com. About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.
Twilfit butiker sthlm

lo 27 coordinates
erik nilsson china
hälsocoach biomedicin
beställa f skattebevis
ramlösa montessori
bästa bloggportalen 2021

Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com

email this chart printer-friendly format.